documents incorporated reference incorporated scheringplough corporation parts ii iv annual report shareholdersscheringplough corporation proxy part iii statement annual meeting shareholders april part item business terms scheringplough company used herein refer scheringplough corporation subsidiaries except otherwise indicated context scheringplough corporation holding company incorporated trademarks indicated capital letters property licensed promoted distributed scheringplough corporation subsidiaries related companies subsidiaries scheringplough engaged discovery development manufacturing marketing pharmaceutical products worldwide discovery development efforts target field human health occasionally application field animal health result efforts company views animal health applications means maximize return investments discovery development company operates primarily prescription pharmaceutical marketplace however appropriate company sought may future seek regulatory approval switch prescription products overthecounter otc status means extending product 's life cycle way otc marketplace yet another means maximizing return investments discovery development one example company 's applications currently pending federal food drug administration fda switch indications market formulations company 's claritin brand nonsedating antihistamine otc products prescription products include celestamine clarinex claritin claritind claritin syrup nasonex polaramine proventil vanceril allergyrespiratory caelyx cedax eulexin garamycin intron pegintron rebetol ribavirin rebetron combination therapy containing rebetol capsules intron injection remicade temodar antiinfective anticancer diprolene diprosone elocon lotrisone quadriderm valisone dermatologicals imdur integrilin kdur nitrodur cardiovasculars celestone diprospan subutex pharmaceuticals animal health products include cepravin nuflor antimicrobials banamine nonsteroidal antiinflammatory ralgro growth promotant implant otomax otic producta broad range vaccines many species parasiticides sutures bandages nutritional products foot care otc sun care products include clear away wart remover dr scholl 's foot care products lotrimin af tinactin antifungals ointment afrin nasal decongestant chlortrimeton antihistamine coricidin drixoral cold decongestant products correctol laxative bain de soleil coppertone solarcaine sun care products net sales major product therapeutic category dollars millions years ended december percent change allergy respiratory claritinclarinex nasonex proventil vanceril vancenase allergy respiratory antiinfective anticancer intron franchise temodar remicade nm eulexin antiinfective anticancer cardiovasculars integrilin kdur nitrodur imdur cardiovasculars dermatologicals elocon lotrisone dermatologicals pharmaceuticals worldwide pharmaceuticals animal health foot care otc sun care consolidated net sales nm meaningful intron franchise consists intron pegintron longeracting form intron monotherapy treating hepatitis c combination rebetol capsules rebetron combination therapy containing rebetol capsules intron injection segment information set forth notes consolidated financial statements company 's annual report shareholders incorporated herein reference prescription drugs introduced made known physicians pharmacists hospitals managed care organizations buying groups trained professional sales representatives sold hospitals certain managed care organizations wholesale distributors retail pharmacists prescription products also introduced made known journal advertising direct mail advertising distributing samples physicians television radio internet print advertising media animal health products promoted veterinarians distributors animal producers foot care otc sun care products sold wholesale retail drug food chain mass merchandiser outlets promoted directly consumer television radio internet print advertising media pharmaceutical industry highly competitive includes large companies substantial resources research product development advertising promotion field selling support numerous domestic international competitors industry principal competitive techniques used company products include research development new improved products high product quality varied dosage forms strengths switching prescription products nonprescription status united states many company 's products subject increasingly competitive pricing managed care groups institutions federal state government entities agencies buying groups seek price discounts rebates governmental pressures toward dispensing generic products may significantly reduce sales certain products become longer protected patents data exclusivity arrangements fda company 's subsidiaries licensed rights number patents patent applications united states abroad patents patent applications relating company 's significant products including without limitation clarinex claritin family products intron rebetron combination therapy containing rebetol capsules intron injection pegintronr ebetol nasonex material importance companyc ertain claritin loratadine related patents expire next several years compound patent loratadine set expire june us market exclusivity claritin extended fda december company conducted pediatric clinical trials request fda compound patent desloratadine set expire april us market exclusivity clarinex extended fda october company conductedpediatric clinical trials request fda patents subject litigation described item legal proceedings claritin loratadine sales united states formulations accounted percent company 's consolidated worldwide sales larger percentage company 's consolidated earnings company sued drug manufacturers seeking market certain forms generic prescription otc loratadine prior expiration certain company 's us patents including compound patents loratadine desloratadine case company filed suit federal court seeking ruling applicable abbreviated new drug application anda paper new drug application submission proposed marketing generic prescription otc product constitute willful infringement company 's patents challenge patents without merit company prevail suits reasonably possible generic prescription otc forms loratadine could enter market early december possible otc claritin could introduced us market prior expiration company 's patentsa company announced march fda accepted filing supplemental new drug applications sndas switch indications market formulations claritin brand nonsedating antihistamine otc productst applications assigned standard review fda targeted action date november company also reported part previously scheduled meeting april fda 's nonprescription drug advisory committee consider among scheduled items whether loratadine appropriately labeled treat chronic idiopathic urticaria ciu otc setting management believes either introduction generic prescription otc loratadine otc claritin us market would likely rapid sharp material adverse effect company 's results operations beginning occurrence event extending indeterminate period time thereafter effect company 's results operations may mitigated company successful patent litigation described item legal proceedings worldwide company 's products sold trademarks trademarks considered aggregate material importance business protected registration common law united states markets products sold raw materials essential company available adequate quantities number potential suppliers energy expected available company sufficient quantities meet operating requirements seasonal patterns pronounced effect consolidated operations company percent percent percent respectively consolidated net sales made mckesson corporation major pharmaceutical health care products distributor also percent percent percent respectively consolidated net sales made amerisourcebergen corporation major pharmaceutical health care products distributor substantially sales united states foreign operations foreign activities carried primarily whollyowned subsidiaries wherever market potential adequate circumstances permit addition company represented markets licensees distribution arrangements approximately employees outside united states foreign operations subject certain risks inherent conducting business overseas risks include possible nationalization expropriation importation limitations pricing restrictions restrictive governmental actions economic destabilization also fluctuations foreign currency exchange rates impact company 's consolidated financial results additional information foreign operations see management 's discussion analysis operations financial condition segment information company 's annual report shareholders incorporated herein reference research development company 's research activities primarily aimed discovering developing new enhanced prescription products medical commercial significance company sponsored research development expenditures million million million respectively research expenditures represented approximately percent consolidated net sales approximately percent consolidated net sales approximately percent consolidated net sales company 's research activities concentrated therapeutic areas allergic inflammatory disorders infectious diseases oncology cardiovascular diseases central nervous system disorders company also substantial efforts directed toward biotechnology gene therapy immunology research activities include expenditures internal research efforts research collaborations various partners several pharmaceutical compounds varying stages development predicted compounds become available commercial sale among products awaiting fda approval march last day prior printing report zetia ezetimibe tablets cardiovascular product developed merckscheringplough pharmaceuticals joint venture clarinex asmanex mometasone furoate allergyrespiratory products also claritin filed marketing approval japan noted item company filed sndas switch indications market formulations claritin otc products government regulation pharmaceutical companies subject extensive regulation number national state local agencies particular importance fda jurisdiction company 's businesses administers requirements covering testing approval safety effectiveness manufacturing labeling marketing company 's products extent fda requirements andor reviews affects amount resources necessary develop new products bring market united states ongoing basis fda regulates facilities procedures used manufacture pharmaceutical products united states sale united states products made facilities manufactured accordance good manufacturing practices gmps established fdat fda periodically inspects company 's facilities procedures evaluate compliance fda conducting inspections company 's manufacturing facilities new jersey puerto rico issued reports citing deficiencies concerning compliance current gmps primarily relating production processes controls procedures continuing evaluate issues raised information provided company connection fda inspections company taken extensive measures intended enhance manufacturing processes controls company notes fda 's inspection reports internal reviews indicate improvements required december company announced negotiations fda consent decree resolve issues involving company 's compliance current gmps manufacturing facilities new jersey puerto rico although company notes number issues discussed assure negotiated agreement reached terms agreement would company believes probable consent decree ultimately entered fda leading payment million agreement would subject approval us district court district new jersey failure comply governmental regulations result delays release products delays approvals new products seizure recall products suspension revocation authority necessary production sale products fines civil criminal sanctions fda also regulates conversion pharmaceuticals prescription overthecounter otc status may fda held joint meeting nonprescription drugs advisory committee pulmonaryallergy drugs advisory committee consider citizens ' petition filed fda health insurance company requesting loratadine two antihistamines marketed companies switched prescription otc status panel voted non binding recommendation loratadine safety profile acceptable otc marketing panel also serious concerns regarding appropriate otc labeling additional issues lack use studies well patient access also noted company record fda opposing switch prescription medications otc status without consent company holds new drug application nda management recognizes medical public policy business environment operates static light changing environment company filed sndas fda accepted filing fda switch indications market formulations claritin brand otc products applications assigned standard review fda targeted action date november april fda 's nonprescription drug advisory committee consider among scheduled items whether loratadine appropriately labeled treat chronic idiopathic urticaria ciu otc setting company 's activities outside united states also subject regulatory requirements governing testing approval safety effectiveness manufacturing labeling marketing company 's products regulatory requirements vary country country whether fda approval approval european medicines evaluation agency obtained product approval product comparable regulatory authorities countries outside united states european union case may must obtained prior marketing product countries approval process may less rigorous country country time required approval may longer shorter required united states approval one country assure product approved another country international markets company operates environment governmentmandated costcontainment programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs enacted acrosstheboard price cuts methods cost control recent years various legislative proposals offered congress many state legislatures would effect major changes affected health care systems one change could material company possible addition outpatient prescription drug benefit medicare states passed legislation federal state legislative administrative proposals possible could include price patient reimbursement constraints medicines mandated discounts supplemental rebates expansion existing governmental programs new patient populations restrictions access certain products similar issues also arisen many countries outside united states possible predict outcome initiatives effect operations cash flows reasonably estimated company also subject jurisdiction various federal state regulatory enforcement departments agencies federal trade commission ftc department justice department health human services united states company therefore subject possible administrative legal proceedings actions organizations actions may result imposition civil criminal sanctions may include finespenalties injunctive administrative remedies environment date compliance federal state local environmental protection laws materially adverse effect company company made continue make necessary expenditures environmental protection worldwide capital expenditures included approximately million environmental control purposes anticipated continued compliance environmental regulations significantly affect company 's financial statements competitive position additional information environmental matters see legal environmental matters notes consolidated financial statements company 's annual report shareholders incorporated herein reference employees approximately people employed company december cautionary factors may affect future results cautionary statements private securities litigation reform act report written reports oral statements made time time company may contain socalled forwardlooking statements subject risks uncertainties one identify forwardlooking statements use words expects plans estimates forecasts projects believes anticipates words similar meaning one also identify fact relate strictly historical current facts statements likely address company 's growth strategy financial results regulatory issues status product approvals development programs litigation investigations one must carefully consider statement understand many factors could cause actual results differ company 's forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement although possible predict identify factors may include following significant portion net sales made major pharmaceutical health care products distributors major retail chains united states consequently net sales quarterly growth comparisons may affected fluctuations buying patterns major distributors retail chains trade buyers fluctuations may result seasonality pricing wholesaler buying decisions factors competitive factors including technological advances attained competitors patents granted competitors new products competitors coming market new indications competitive products generic prescription otc competition company 's products mature patents expire products increased pricing pressure united states abroad managed care organizations institutions government agencies programs united states among developments consolidation among customers may increase pricing pressures may result various customers greater influence prescription decisions formulary decisions policies government laws regulations changes laws regulations affecting domestic international operations enforcement thereof including among laws regulations resulting healthcare reform initiatives united states state federal level countries well laws regulations relating trade antitrust monetary fiscal policies taxes price controls possible nationalization patent positions highly uncertain patent disputes unusual adverse result patent dispute preclude commercialization products negatively impact sales existing products result injunctive relief payment financial remedies uncertainties fda approval process regulatory approval processes nonus countries including without limitation delays approval new products failure meet gmps established fda governmental authorities result delays release products seizure recall products suspension revocation authority necessary production sale products fines civil criminal sanctions resolution manufacturing issues fda discussed report subject substantial risks uncertainties risks uncertainties including timing scope duration resolution manufacturing issues depend ability company assure fda quality reliability manufacturing systems controls extent remedial prospective obligations undertaken company difficulties product development pharmaceutical product development highly uncertain products appear promising development may fail reach market numerous reasons may found ineffective harmful side effects clinical preclinical testing may fail receive necessary regulatory approvals may turn economically feasible manufacturing costs factors may precluded commercialization proprietary rights othersefficacy safety concerns respect marketed products whether scientifically justified leading recalls withdrawals declining sales major products claritin intron pegintron rebetron combination therapy rebetol capsules nasonex accounted material portion company 's revenues major product become subject problem loss patent protection otc competition previously unknown side effects new effective treatment introduced product discontinued reason impact revenues could significant noted item business management believes either introduction generic prescription otc loratadine otc claritin us market would likely rapid sharp material adverse effect company 's results operations beginning occurrence event extending indeterminate period time thereafter effect company 's results operations may mitigated company successful patent litigation described item legal proceedings legal factors including product liability claims litigation government investigations patent disputes competitors environmental concerns could preclude commercialization products negatively affect profitability existing products economic factors company control including changes inflation interest rates foreign currency exchange rates changes tax laws including changes related taxation foreign earnings changes accounting standards promulgated american institute certified public accountants financial accounting standards board securities exchange commission adverse company item properties company 's corporate headquarters located kenilworth new jersey principal manufacturing facilities located kenilworth new jersey miami florida omaha nebraska cleveland tennessee puerto rico argentina belgium canada france germany ireland italy japan mexico singapore spain company 's principal research facilities located kenilworth union new jersey palo alto san diego california elkhorn nebraska major portion properties owned company properties well maintained adequately insured good operating condition company 's manufacturing facilities capacities considered appropriate meet company 's needs item legal proceedings subsidiaries company defendants lawsuits involving approximately plaintiffs arising use synthetic estrogens mothers plaintiffs virtually lawsuits many pharmaceutical companies also named defendants female plaintiffs claim various injuries including cancerous precancerous lesions vagina cervix multiplicity pregnancy problems number suits involve infants birth defects born daughters whose mother took drug total amount claimed defendants suits amounts billion possible precisely predict outcome proceedings management 's opinion remote material liability excess amount accrued incurred company party otherwise involved environmental cleanup actions proceedings comprehensive environmental response compensation liability act commonly known superfund equivalent state laws actions proceedings seek require owners operators facilities treated stored disposed hazardous substances transporters generators substances remediate contaminated facilities andor reimburse government private parties cleanup costs company along owners operators transporters generators alleged potentially responsible party prp alleged generator hazardous substances found certain facilities proceeding government private litigants allege one prp including company jointly severally liable cleanup requirements costs although joint several liability alleged prp 's share cleanup costs frequently determined basis several factors including type quantity hazardous substances however allocation process varies greatly facility facility may take years complete company 's potential share cleanup costs also depends many prps involved action proceeding insurance coverage available indemnity contracts contribution rights prps possible predict certainty outcome action proceeding management 's opinion remote material liability excess amounts accrued incurred residents vicinity publicly owned wastewater treatment plant barceloneta puerto rico filed two lawsuits plant owner operator numerous companies discharge plant including subsidiary company damages injunctive relief relating odors allegedly coming plant connecting sewers one lawsuits class action claiming damages million lawsuits early stages discovery possible predict outcomethe company defendant numerous antitrust actions commenced starting state federal courts independent retail pharmacies chain retail pharmacies consumers plaintiffs allege price discrimination andor conspiracy company defendants restrain trade jointly refusing sell prescription drugs discounted prices plaintiffs one federal cases class action behalf approximately twothirds retail pharmacies united states alleged pricefixing conspiracy company february agreed settle federal class action total million paid full united states district court illinois approved settlement federal class action june june seventh circuit court appeals dismissed appeals settlement subject review defendants settle class action proceeded trial september trial ended november directed verdict defendants ' favor april certain plaintiffs federal class action commenced another purported class action united states district court illinois company defendants settled previous federal class action complaint alleges defendants conspired implement settlement commitments following settlement discussed district court denied plaintiffs ' motion preliminary injunction hearing company settled state court retailer actions except one alabama settlement amounts material company june alabama supreme court reversed denial motion judgment pleadings alabama retailer case court held alabama antitrust law apply conspiracies alleged interstate commerce based ruling alabama retailer case dismissed subsequently district attorney first judicial circuit filed complaint behalf alabama consumers state 's deceptive trade practices act federal court illinois recently remanded cases retailers opted class action back district courts filed plaintiffs antitrust actions generally seek treble damages unspecified amount injunction allegedly unlawful conduct company believes antitrust actions without merit defending vigorously october company received subpoena us attorney 's office eastern district pennsylvania pursuant health insurance portability accountability act concerning company 's contracts pharmacy benefit managers pbms managed care organizations provide disease management services connection marketing pharmaceutical products appears subpoena one number addressed industry participants part inquiry among things pharmaceutical marketing practices government 's inquiry focused among things whether company 's disease management marketing programs arrangements comply federal health care laws whether value disease management programs marketing programs arrangements included calculation rebates government company cooperating investigation march us attorney 's office began issuing grand jury subpoenas grand jury investigation appears focused one transactions managed care organizations government believes company offered provided deeply discounted pharmaceutical products known nominally priced products generally excluded medicaid rebate calculations free discounted disease management services marketing programs arrangements delivered value order place retain one company 's major pharmaceutical products managed care organization 's formulary grand jury appears investigating among things whether transactions described conduct relating thereto violated federal antikickback statutes ii whether value items services described included company 's calculation medicaid rebates possible predict outcome investigations could include commencement civil criminal proceedings involving fines penalties injunctive administrative remedies including exclusion government reimbursement programs company predict whether investigations affect marketing practices sales february geneva pharmaceuticals inc geneva submitted abbreviated new drug application anda us fda seeking market generic form claritin united states several years expiration company 's patents geneva alleged certain company 's us claritin patents invalid unenforceablet claritin patents material company 's business march company filed suit federal court seeking ruling geneva 's anda submission constitutes willful infringement company 's patents challenge company 's patents without merit company believes prevail suit however litigation assurance company prevail copley pharmaceutical inc teva pharmaceuticals usa inc novex pharma zenith goldline pharmaceuticals individually notified company submitted anda fda seeking market certain generic forms claritin united states expiration certain company 's patents including compound patents loratadine desloratadine andrx pharmaceuticals llc andrx mylan pharmaceuticals inc esi lederle inc lederle impax laboratories inc made similar submissionsin alpharma uspd inc ranbaxy pharmaceuticals inc taro pharmaceuticals usa inc genpharm incorporated made similar submissionsa nd andrx submitted another anda fda market second formulation generic claritina lso mcneil consumer healthcare mcneil submitted paper new drug application paper nda section b federal food drug cosmetic act seeking market generic otc form claritin expiration company 's patentsin whitehallrobins healthcare division american home products wyeth march made similar paper nda submission alleged one patents invalid unenforceable case thecompany filed suit federal court seeking ruling applicable anda paper nda submission proposed marketing generic prescription otc product constitute willful infringement company 's patents challenge patents without merit company believes prevail suits however litigation assurance company prevail company codefendant litigation commenced october housey pharmaceuticals pharmaceutical companies housey alleged infringement several patents relating laboratory research methods company believes substantial defenses defend vigorously however litigation assurance company prevail company responding investigations department health human services department justice certain states certain industry company practices regarding average wholesale price awp investigations include department justice review merits federal action filed private entity behalf united states united states district court southern district florida well investigation united states attorney 's office district massachusetts regarding inter alia whether awp set pharmaceutical companies certain drugs improperly exceeds average prices paid dispensers consequence results unlawful inflation certain government drug reimbursements based awp us attorney 's office district massachusetts also investigating whether company 's sales product repackaged sale managed care organization included company 's medicaid best price calculations march company received subpoena massachusetts attorney general 's office seeking documents concerning use awp pricing andor marketing practices company cooperating investigations possible predict outcome investigations could include imposition fines penalties injunctive administrative remedies third quarter company 's generic subsidiary warrick pharmaceuticals warrick sued state texas lawsuit alleges warrick supplied state false reports wholesale prices caused state pay medicaid claims prescriptions warrick 's albuterol sulfate solution higher justified level state seeks damages million warrick including treble damages penalties possible predict outcome litigation could result imposition fines penalties injunctive administrative remedies october west virginia attorney general filed lawsuit warrick alleging warrick falsely inflated awp albuterol sulfate solution knowing state medicaid programs state programs relied awp pay providers drugs complaint alleges warrick caused state pay excessive reimbursement distributors drug complaint demands unspecified damages including treble damages attorneys ' fees company believes claims without merit defend vigorously however litigation assurance company prevail november private plaintiff filed complaints arizona state court company warrick complaints alleged suitable class action status allege company warrick engaged conspiracy fraudulently report fictitious awps regarding prescription pharmaceuticals inflated awps allegedly supplied medicaid medicare private insurers lawsuits seek unspecified damages including treble damages attorneys ' fees company believes claims without merit defend vigorously however litigation assurance company prevail january nevada attorney general filed lawsuit warrick alleging warrick engaged scheme fraudulently report fictitious awps prescription pharmaceuticals covered medicare medicaid thus inflating reimbursements patients ' copayments lawsuit also alleges warrick failed report accurate prices medicaid rebate program thereby underpaid medicaid rebates required pay nevadat lawsuit seeks injunctive relief unspecified damages including treble punitive damages company believes claims without merit defend vigorously however litigation assurance company prevail february montana attorney general filed lawsuit company warrickn either company warrick served lawsuit alleges defendants reported inflated awps supplied medicare medicaid montana state agencies inflated awps allegedly caused state patients made copayments overpay certain drugs complaint also alleges defendants failed report accurate prices medicaid rebate program thereby deprived state proper rebates complaint seeks injunctive relief unspecified damages including double damages company believes claims without merit defend vigorously however litigation assurance company prevail january warrick served lawsuit filed united states district court district nevada twin cities bakery workers health welfare fund another plaintiff case alleges class action behalf direct indirect endpayers medicarecovered pharmaceuticals sold warrick case alleges violations section sherman act federal rico statutory fraud unjust enrichment laws alleged overpayments result inflated awps alleged giving free samples expecting samples would billed medicare end payers complaint seeks treble punitive damages injunctive relief company believes claims without merit defend vigorously however litigation assurance company prevail april ftc started administrative proceeding company upshersmith inc upshersmith lederle complaint alleges anticompetitive effects settlement patent lawsuits company lederle company upshersmith lawsuits settled related generic versions kdur thecompany 's longacting potassium chloride product subject andas filed lederle upshersmitht administrative hearing began january company believes actions lawful proper intends defend vigorously however possible predict outcome proceeding could result imposition injunctive administrative remedies following commencement ftc administrative proceeding alleged class action suits filed behalf direct indirect purchasers kdur company upshersmith lederle federal state courtst hese suits allege essentially facts claim violations federal state antitrust laws well state statutory andor common law causes action company believes substantial defenses intends defend vigorously january jury found company 's prime pac prrs porcine respiratory reproductive syndrome vaccine infringed patent owned boehringer ingelheim vetmedica inc injunction issued august barring sales company 's vaccine company 's posttrial motions either reversal jury 's verdict new trial denied september company appealed litigation assurance company prevail february company stated press release fda conducting inspections company 's manufacturing facilities new jersey puerto rico issued reports citing deficiencies concerning compliance current good manufacturing practices primarily relating production processes controls procedures next day february lawsuit filed united states district court district new jersey company certain named officers alleging violations sections b securities exchange act rule b promulgated thereunder additional lawsuits tenor followed plaintiffs suits purport represent classes shareholders purchased shares company stock dates early march february date press release april lawsuit filed united states district court district new jersey company certain named officers alleging substantially violations securities exchange act alleged putative class actions described paragraph well alleging violations section securities act failure disclose information subject matter ftc administrative proceeding described purporting represent class shareholders purchased shares company stock july march last business day company issued press release relating ftc administrative proceeding complaint previously filed complaints consolidated one action united states district court district new jersey lead plaintiff florida state board administration appointed court july october consolidated amended complaint filed alleging violations described second sentence paragraph section claim purporting represent class shareholders purchased shares company stock may february company moved dismiss consolidated amended complaint company believes substantial defenses intends defend consolidated action vigorously addition lawsuits described immediately preceding paragraph two lawsuits filed united states district court district new jersey two lawsuits filed new jersey state court company nominal defendant certain officers directors former director seeking damages behalf company including disgorgement trading profits made defendants allegedly obtained basis material nonpublic information complaints four lawsuits relate issues described company 's february press release allege failure disclose material information breach fiduciary duty directors one federal court lawsuits also includes allegations related investigations us attorney 's offices eastern district pennsylvania district massachusetts ftc 's administrative proceeding company lawsuit state texas warrick described lawsuits shareholder derivative action purports assert claims behalf company demand made board directors decision made whether company pursue claims august plaintiffs new jersey state court shareholder derivative actions moved dismiss voluntarily complaints actions motions granted two shareholder derivative actions pending united states district court district new jersey consolidated one action early stages consolidated action coordinated pretrial purposes consolidated action described immediately preceding paragraph january corporation received demand letter dated december law firm involved derivative actions described behalf shareholder also involved derivative actions demanding board directors bring claims behalf company based allegations substantially similar alleged derivative actions january board directors adopted board resolution establishing evaluation committee consisting three directors investigate review analyze facts circumstances surrounding allegations made demand letter consolidated amended derivative action complaint described reserving full board authority discretion exercise business judgment respect proper disposition demand committee engaged independent outside counsel advise company party arbitration commenced july biogen inc biogen relating among things biogen 's claims company owes us alpha interferon royalty payments biogen period time company believe royalties owed preempt future royalty disputes biogen 's claims relate company 's sale intron pegintron second arbitration commenced biogen company august relating biogen 's claim company owed royalties intron provided without charge reduced charge indigent patients participating schering 's commitment care programin october icn pharmaceuticals inc icn also notified company intention begin alternative resolution dispute proceeding company seeking payment royalties rebetol provided company without charge reduced charge indigent patientsparticipating schering 's commitment care progratmhe company believes biogen 's claims proceedings icn 's claims without merit defend vigorously however arbitration alternative dispute proceeding assurance company prevail august prescription access litigation pal project bostonbased group formed litigate drug companies issued press release stating pal members filed lawsuit new jersey state court company december company served amended complaint case suit pal purports class action alleges among things company 's directtoconsumer advertising falsely depicts benefits claritin violation new jersey consumer fraud act company believes claims without merit defend vigorously february company filed motion dismiss case however litigation assurance company prevail december pal filed class action suit federal court massachusetts companyt complaint alleges company conspired drug companies defraud consumers reporting fraudulently high awps prescription medications covered medicare complaint seeks declaratory judgment unspecified damages including treble damages company believes claims without merit defend vigorously however litigation assurance company prevail company received notice august geneva pharmaceuticals technology corp geneva pharmaceuticals three rivers pharmaceuticals llc three rivers january teva pharmaceuticals usa inc teva submitted separate andas fda seeking market generic forms mg rebetol ribavirin capsules united states expiration company 's patents covering ribavirin formulations geneva pharmaceuticals three rivers teva asserted infringe company 's rebetol patents andor patents invalidt rebetol patents material company 's business september october march company filed suits federal court seeking rulings anda submissions geneva pharmaceuticals three rivers teva respectively constitute infringement company 's patents challenges company 's patents without merit company believes prevail suits however litigation assurance company prevail october united states internal revenue service irs auditors asserted reports company liable additional tax tax years reports allege two interest rate swaps company entered unrelated party recharacterized loans affiliated companies resulting additional tax income tax sought irs auditors relating recharacterization approximately million plus penalties interest period stated company tax advisers believe merit irs ' positiont company intends defend position vigorously however assurance company prevail company defendant number purported nationwide state class action lawsuits plaintiffs seek refund purchase price phenylpropanolaminecontaining coughcold remedies laxatives recalled albuterolvanceril inhalers purchased pharmaceutical manufacturers codefendants lawsuits general plaintiffs claim would purchased products known certain medical risks attendant use would purchased products reduced price known risks lawsuits early stages discovery plaintiffs ' theories recovery yet legally tested courts yet agreed cases go forward class actions number lawsuits also filed company seeking recovery personal injuries death several lawsuits punitive damages claimed company believes prevail suits however litigation assurance company prevail item submission matters vote security holders applicable executive officers registrant following information regarding executive officers included herein accordance part iii item officers elected serve one year successors shall duly elected name current position business experience age richard jay kogan chairman board chief executive officer since president chief executive chairman board officer chief executive officer andpresident reelected office president joseph c connors present position executive vice president general counsel jack l wyszomierski present position executive vice president chief financial officer geraldine u foster present position senior vice president investor relations corporate communications daniel nichols present position senior vice president taxes john p ryan present position senior vice president vice president human resources human resources scheringplough pharmaceuticals name current position business experience age roch f doliveux present position vice president president scheringplough president scheringplough international international senior vice president managed care health management douglas j gingerella present position vice president corporate staff vice president corporate audits audits thomas h kelly present position vice president controller robert lyons present position vice president corporate information services e kevin moore present position vice president treasurer richard w zahn present position vice president president schering laboratories president schering laboratories joseph j larosa present position staff vice president staff vice president commercial law secretary associate senior legal director general counsel legal director part ii item market registrant 's common equity related stockholder matters common share dividends share price data approximate number holders record set forth company 's annual report shareholders incorporated herein reference item selected financial data sixyear selected financial statistical data set forth company 's annual report shareholders incorporated herein reference item management 's discussion analysis financial condition results operations management 's discussion analysis operations financial condition set forth company 's annual report shareholders incorporated herein reference item quantitative qualitative disclosures market risk market risk disclosures set forth management 's discussion analysis operations financial condition company 's annual report shareholders incorporated herein reference item financial statements supplementary data consolidated balance sheets december related statements consolidated income consolidated shareholders ' equity consolidated cash flows three years period ended december notes consolidated financial statements independent auditors ' report deloitte touche llp dated february unaudited quarterly data set forth company 's annual report shareholders incorporated herein reference item changes disagreements accountants accounting financial disclosure applicable part iii item directors executive officers registrant information concerning directors nominees directors set forth company 's proxy statement annual meeting shareholders april incorporated herein reference information required executive officers included part filing caption executive officers theregistrant item executive compensation executive compensation information set forth company 's proxy statement annual meeting shareholders april incorporated herein reference item security ownership certain beneficial owners management information concerning security ownership certain beneficial owners management set forth company 's proxy statement annual meeting shareholders april incorporated herein reference item certain relationships related transactions information concerning certain relationships related transactions set forth company 's proxy statement annual meeting shareholders april incorporated herein reference part iv item exhibits financial statement schedules reports form k financial statements following consolidated financial statements independent auditors ' report included company 's annual report shareholders incorporated herein reference statements consolidated income years ended december statements consolidated cash flows years ended december consolidated balance sheets december statements consolidated shareholders ' equity years ended december notes consolidated financial statements independent auditors ' report financial statement schedules form kindependent auditors ' report schedule ii valuation qualifying accounts schedules included omitted applicable required required information set forth financial statements notes thereto columns omitted schedules filed omitted information applicable financial statements fifty percent less owned companies accounted equity method omitted considered individually aggregate constitute significant subsidiary exhibits exhibit number description complete copy certificate incorporation amended currently effect incorporated reference exhibit company 's quarterly report period ended june form q certificate amendment certificate incorporation incorporated reference exhibit company 's quarterly report period ended june form q certificate amendment certificate incorporation incorporated reference exhibit company 's quarterly report period ended march form q file b complete copy bylaws amended currently effect incorporated reference exhibit company 's registration statement form file amendment bylaws effective september incorporated reference exhibit company 's quarterly report period ended september form q amendment bylaws effective april incorporated reference exhibit company 's quarterly report period ended march form q amendment bylaws effective december filed document file rights agreement company bank new york dated june incorporated reference exhibit form filed company june file b indenture dated november company chase manhattan bank na trustee incorporated reference exhibit company 's registration statement form file c form participation rights agreement company chase manhattan bank national association trustee incorporated reference exhibit company 's registration statement form amendment file exhibit description number company 's executive incentive plan amended trust related theretop lan incorporated reference exhibit company 's quarterly report period ended march form q executive incentive plan amended restated october incorporated reference exhibit company 's annual report file ii trust agreement incorporated reference exhibit company 's annual report amendment trust agreement incorporated reference exhibit b company 's quarterly report period ended march form q amended restated defined contribution trust incorporated reference exhibit aii company 's annual report file b company 's stock incentive plan amendedi ncorporated reference exhibit company 's annual report file c company 's stock incentive plan amended incorporated reference exhibit company 's annual report file amendment december incorporated reference exhibit company 's annual report file company 's stock incentive plani ncorporated reference exhibit company 's quarterly report period ended september form q amendment stock incentive plan incorporated reference exhibit company 's quarterly report period ended march form q file description exhibit number e employment agreement company richard jay kogan amended incorporated reference exhibit eii company 's annual report first amendment incorporated reference exhibit b company 's quarterly report period ended june form q second amendment incorporated reference exhibit eii company 's annual report third amendment incorporated reference exhibit company 's quarterly report period ended september form q fourth amendment incorporated reference exhibit b company 's quarterly report period ended march form q fifth amendment incorporated reference exhibit eii company 's annual report file e ii form employment agreement company executive officers effective upon change control incorporated reference exhibit eiv company 's annual report form amendment incorporated reference exhibit company 's quarterly report period ended september form q forms amendment effective january filed document exhibits e ii b form employment agreement company executive officers effective upon change control incorporating prior amendments january new agreements effective beginning january filed document exhibit e ii c file e iii employment agreement company raul e cesan incorporated reference exhibit evi company 's annual report file e iv employment agreement company robert p luciano amended incorporated reference exhibit ei company 's annual report first amendment incorporated reference exhibit company 's quarterly report period ended june form q second amendment incorporated reference ei company 's annual report third amendment incorporated reference exhibit company 's quarterly report period ended march form q file description exhibit number ev agreement company robert p luciano incorporated reference exhibit company 's quarterly report period ended march form q file evi supplement employment agreement effective upon change control described exhibit eii document index company joseph c connors filed document file evii supplement employment agreement effective upon change control described exhibit eii document index company jack wyszomierski filed document file eviii supplement employment agreement effective upon change control described exhibit eii document index company richard w zahn filed document file f amended restated directors deferred compensation plan trust related thereto incorporated reference exhibit b company 's quarterly report period ended september form q trust agreement incorporated reference exhibit company 's annual report amendment trust agreement incorporated reference exhibit b company 's quarterly report period ended march form q amended restated defined contribution trust incorporated reference exhibit aii company 's annual report file description exhibit number g supplemental executive retirement plan trust related thereto incorporated reference exhibit e company 's quarterly report period ended march form q amendment incorporated reference exhibit company 's quarterly report period ended september form q second amendment supplemental executive retirement plan effective october incorporated reference exhibit g company 's annual report amended restated trust agreement incorporated reference exhibit g company 's annual report file h amended restated directors ' stock award plan incorporated reference exhibit c company 's quarterly report period ended september form q file deferred compensation plan incorporated reference exhibit b company 's quarterly report period ended september form q deferred compensation plan amended restated october incorporated reference exhibit h company 's annual report file j amended restated directors deferred stock equivalency programi ncorporated reference exhibit company 's quarterly report period ended september form q file k company 's form split dollar agreement related collateral assignment company executive officers incorporated reference exhibit l company 's annual report amendments incorporated reference exhibit g company 's quarterly report period ended march form q file exhibit description number l company 's retirement benefits equalization plan second amendment effective october incorporated reference exhibit l company 's annual report incorporated reference exhibit f company 's quarterly report period ended march form q amendment incorporated reference exhibit b company 's quarterly report period ended september form q file computation ratio earnings fixed charges filed document financial section company 's annual report shareholdersw ith exception portions said annual report specifically incorporated reference filed document report shall deemed filed part subsidiaries registrant filed document consents experts counsel filed document power attorney filed document press releases dated february april april june june june releases july incorporated reference